AR083533A1 - Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe - Google Patents

Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe

Info

Publication number
AR083533A1
AR083533A1 ARP110103916A ARP110103916A AR083533A1 AR 083533 A1 AR083533 A1 AR 083533A1 AR P110103916 A ARP110103916 A AR P110103916A AR P110103916 A ARP110103916 A AR P110103916A AR 083533 A1 AR083533 A1 AR 083533A1
Authority
AR
Argentina
Prior art keywords
protein
treatment
nucleic acid
amino acid
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP110103916A
Other languages
English (en)
Inventor
Mauricio Alberto Realpe-Quintero
Konrad Stadler
Eric Martin Vaughn
Kempis Maria Del Rocio Leon
Paulino Carlos Gonzales-Hernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Vetmedica de C V SA filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of AR083533A1 publication Critical patent/AR083533A1/es
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se provee además una molécula de ácido nucleico que codifica la proteína H5 del virus de la gripe, vector que comprende dicho ácido nucleico.Reivindicación 1: Proteína H5 del virus de la gripe, caracterizada porque la proteína H5 tiene (a) los aminoácidos 113D, 126H, 145(-), 156R, 160F, 167T, y 181N, en los que la modificación 145(-) significa que la posición del aminoácido 145 de H5 está delecionada, o (b) los aminoácidos 87P, 145L, 172T, 201E, 206I, 208K, 254T, 341G y 421K, o (c) los aminoácidos 145L, 172T, y 254V, y en los que la numeración de las posiciones de aminoácidos de la proteína H5 se refiere a la posición de aminoácido dada como ejemplo en la SEQ ID Nº 1, o (d) donde la proteína H5 comprende o consiste en una secuencia de aminoácidos que tiene al menos el 95%, preferiblemente al menos 96%, más preferiblemente al menos 97%, aún más preferiblemente al menos 98%, todavía más preferiblemente al menos 99%, o en particular preferiblemente el 100% de homología con una cualquiera de las secuencias indicadas en las SEQ ID Nº 2 a 40. Reivindicación 13: Una vacuna caracterizada porque comprende: a) la proteína H5 según una cualquiera de las reivindicaciones 1 a 10, la molécula de ácido nucleico según la reivindicación 11 o el vector según la reivindicación 12, y b) un vehículo y/o excipiente farmacéuticamente aceptable. Reivindicación 24: Un método para el tratamiento o la profilaxis de infecciones del virus de la gripe, caracterizado porque comprende la administración de una cantidad terapéuticamente eficaz de la proteína H5 según las reivindicaciones 1 a 10, a un sujeto que necesite dicho tratamiento, o donde el método comprende la administración de una cantidad terapéuticamente eficaz del ácido nucleico H5 según la reivindicación 11 o del vector según la reivindicación 12 a un sujeto que necesite dicho tratamiento, o donde el método comprende la administración de una cantidad terapéuticamente eficaz de la vacuna según la reivindicación 13 ó 14, a un sujeto que necesite dicho tratamiento, y donde en uno cualquiera de dichos métodos, la infección de gripe está causada en particular por un virus de la gripe aviar, porcina o humana o por cualquiera de sus combinaciones o híbridos.
ARP110103916A 2010-10-22 2011-10-21 Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe Pending AR083533A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10188576 2010-10-22

Publications (1)

Publication Number Publication Date
AR083533A1 true AR083533A1 (es) 2013-03-06

Family

ID=43734836

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103916A Pending AR083533A1 (es) 2010-10-22 2011-10-21 Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe

Country Status (5)

Country Link
EP (1) EP2630155B1 (es)
CN (1) CN103429611A (es)
AR (1) AR083533A1 (es)
ES (1) ES2798326T3 (es)
WO (1) WO2012054907A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078674A1 (en) * 2012-11-16 2014-05-22 Medimmune, Llc Swine influenza hemagglutinin and neuraminidase variants
SG11201507253XA (en) * 2013-03-15 2015-10-29 Novavax Inc Enhanced expression of picornavirus proteins
WO2015099609A1 (en) * 2013-12-23 2015-07-02 Temasek Life Sciences Laboratory Limited Monovalent h5 vaccine
GB201507723D0 (en) * 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Anti-bacterial agents and their use in therapy
KR20230038416A (ko) 2020-05-08 2023-03-20 아카데미아 시니카 키메릭 인플루엔자 백신
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CA3234653A1 (en) * 2021-10-06 2023-04-13 Diosynvax Ltd Influenza vaccines

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0386185A1 (fr) 1988-07-29 1990-09-12 IntraCel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1026253B2 (en) 1989-03-21 2012-12-19 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5690938A (en) 1989-07-07 1997-11-25 Oravax, Inc. Oral immunization with multiple particulate antigen delivery system
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
EP0528859B1 (en) 1990-04-24 1998-01-21 Flustat Pty. Ltd. Oral vaccine comprising antigen surface-associated with red blood cells
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
ATE181108T1 (de) 1991-08-26 1999-06-15 Immuno Ag Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5807722A (en) 1992-10-30 1998-09-15 Bioengineering Resources, Inc. Biological production of acetic acid from waste gases with Clostridium ljungdahlii
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
DE69536091D1 (de) 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunisierung durch Impfung von DNS Transkriptionseinheit
DK0758397T3 (da) 1994-04-29 2005-10-10 Baxter Healthcare Sa Rekombinante poxvira med fremmede polynucleotider i essentielle regioner
WO1996029421A1 (en) 1995-03-23 1996-09-26 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
DE69740033D1 (de) 1996-07-03 2010-12-09 Merial Inc Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
BRPI0110607B8 (pt) 2000-04-28 2021-05-25 St Jude Childrens Res Hospital sistema baseado em plasmídeos, método para produzir um vírion de vírus com fita rna negativa, método para produzir um vírion orthomyxoviridae, método para produzir um vírion influenza, método para produzir um vírion influenzapatogênico, método para preparar uma vacina específica de vírus rna de fita negativa e método para gerar um vírus rna de fita negativa atenuado
US20020095197A1 (en) 2000-07-11 2002-07-18 Lardo Albert C. Application of photochemotherapy for the treatment of cardiac arrhythmias
BRPI0713671A2 (pt) * 2006-06-16 2013-12-03 Dow Agrosciences Llc Sequências de dna, vetores e proteínas de hemaglutinina de influenza aviária
US10226527B2 (en) * 2010-10-04 2019-03-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto

Also Published As

Publication number Publication date
CN103429611A (zh) 2013-12-04
EP2630155B1 (en) 2020-04-15
ES2798326T3 (es) 2020-12-10
WO2012054907A3 (en) 2012-06-21
WO2012054907A2 (en) 2012-04-26
EP2630155A2 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
AR083533A1 (es) Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
PE20180571A1 (es) Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
ES2691091T3 (es) Vacuna conjugada de péptido antigénico de WT1
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
PE20140986A1 (es) Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae
ES2673556T3 (es) Vacunas para el VHS-2
AR094141A1 (es) Composiciones y metodos para proteinas de accion prolongada
ES2682670T3 (es) Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas
BRPI0923346A2 (pt) Proteinas em super-helice antiparalela de cadeia simples
AR105822A1 (es) Análogos de insulina
MX369469B (es) Vacuna contra el virus respiratorio sincitial.
SI2280721T1 (en) IMUNOTHERAPY BASED ON INDOLEAMINE 2,3-DIOXYGENESIS
CO6210831A2 (es) Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal
AR090439A1 (es) Lipopeptidos antimicrobianos cortos
AR083839A1 (es) Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
RU2015119523A (ru) Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
PE20230343A1 (es) Peptidos que estimulan respuestas inmunitarias antitumorales
AR060960A1 (es) Peptido, polinucleotico, secuencia celula transgenica, huesped viral, celula huesped, vector de expresion, uso y metodo de antagonistas de alta afinidad de quimioquinas elr- cxc
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
AR100824A1 (es) Complejo de poliproteínas inmunogénicas de m. hyopneumoniae, gen sintético codificante del complejo de proliproteínas inmunogénicas de m. hyopneumoniae, composición antigénica, proceso de obtención de un complejo de poliproteínas inmunogénicas de m. hyopneumoniae, uso de una composición con base en el complejo de poliproteínas inmunogénicas de m. hyopneumoniae

Legal Events

Date Code Title Description
FB Suspension of granting procedure